Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanoma

Despite novel therapies for melanoma, drug resistance remains a significant hurdle to achieving optimal responses. NRAS‐mutant melanoma is an archetype of therapeutic challenges in the field, which we used to test drug combinations to avert drug resistance. We show that BET proteins are overexpresse...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :EMBO Mol Med
Главные авторы: Echevarría‐Vargas, Ileabett M, Reyes‐Uribe, Patricia I, Guterres, Adam N, Yin, Xiangfan, Kossenkov, Andrew V, Liu, Qin, Zhang, Gao, Krepler, Clemens, Cheng, Chaoran, Wei, Zhi, Somasundaram, Rajasekharan, Karakousis, Giorgos, Xu, Wei, Morrissette, Jennifer JD, Lu, Yiling, Mills, Gordon B, Sullivan, Ryan J, Benchun, Miao, Frederick, Dennie T, Boland, Genevieve, Flaherty, Keith T, Weeraratna, Ashani T, Herlyn, Meenhard, Amaravadi, Ravi, Schuchter, Lynn M, Burd, Christin E, Aplin, Andrew E, Xu, Xiaowei, Villanueva, Jessie
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2018
Предметы:
Research Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5938620/
https://ncbi.nlm.nih.gov/pubmed/29650805
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201708446
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы